The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1451
ISSUE1451
September 15, 2014
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
September 15, 2014 (Issue: 1451)
The FDA has approved vedolizumab (Entyvio - Takeda),
an intravenous integrin receptor antagonist, for treatment
of moderate to severe ulcerative colitis or Crohn's
disease in adults who have not responded to, lost
response to, or cannot tolerate...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.